Full Press Release Details
Home
Pipeline
Team
Research
NEWS
INVESTORS
Careers
Contact
Array - February 20, 2026
Frequency of Rater-based Efficacy Assessments Correlated with Magnitude of Placebo Response in Generalized Anxiety Disorder Trials
SPTX Neutral Sentiment
Frequency of Rater-based Efficacy Assessments Correlated with Magnitude of Placebo Response in Generalized Anxiety Disorder Trials
Key Takeaway: The article discusses a study on the correlation between the frequency of rater-based efficacy assessments and the magnitude of placebo responses in trials for Generalized Anxiety Disorder. The findings may provide insights into the design and interpretation of clinical trials in this area. Further details on the implications of these findings are not provided.
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceCash runway
~12 mo
Low dilution risk
Lead asset
SPT-300
Phase 2 · Major Depressive Disorder (MDD)
Frequently Asked Questions
What is the focus of the study discussed in the article?
The study focuses on the correlation between rater-based efficacy assessments and placebo responses in Generalized Anxiety Disorder trials.
What disorder is being studied in the trials?
The trials are focused on Generalized Anxiety Disorder.
What is the significance of the findings?
The findings may help improve the design and interpretation of clinical trials for anxiety disorders.